John Miller
Corporate Officer/Principal bei JAZZ PHARMACEUTICALS PLC
Profil
John Miller is currently the Senior Vice President-Corporate Strategy at Jazz Pharmaceuticals Plc.
Prior to his current position, he worked as the Director-US & Global Marketing at Alexion Pharmaceuticals, Inc. in 2012 and as the Director-Strategic Marketing at Enobia Pharma, Inc. from 2011 to 2012.
Mr. Miller completed his undergraduate degree at the University of Mississippi and holds an MBA from the Questrom School of Business.
Aktive Positionen von John Miller
| Unternehmen | Position | Beginn |
|---|---|---|
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01.02.2015 |
Ehemalige bekannte Positionen von John Miller
| Unternehmen | Position | Ende |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.08.2012 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01.02.2012 |
Ausbildung von John Miller
| University of Mississippi | Undergraduate Degree |
| Questrom School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
